New GLP-1 Semaglutide Still Largely Unknown to Endocrinologists

Share this post

Medscape Medical News poll respondents said obese patients with diabetes whose condition is poorly controlled would benefit the most from semaglutide.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply